UroGen Pharma is a biotechnology company that develops and commercializes cancer treatments using its proprietary RTGel platform, a reverse-thermal hydrogel technology that extends the exposure of medications to urinary tract tissues, improving treatment efficacy. The company's approved products include Jelmyto for upper tract urothelial cancer and Zusduri for non-muscle invasive bladder cancer, both combining mitomycin with RTGel to enable longer dwell times and higher drug concentrations than traditional water-based formulations. UroGen generates revenue through direct product sales to urologists and healthcare institutions in the United States, with reimbursement secured through Medicare, commercial insurance, and Medicaid, and maintains a differentiated competitive position through its robust intellectual property portfolio and next-generation pipeline candidates designed to address unmet needs in urothelial and specialty cancers.